Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: Influence on biorheological properties of blood

European Journal of Haematology

Volumn 62, Issue 4, 1999, Pages 223-230

  Reinhart, W H ^d   Baerlocher, G M ^e   Cerny, T ^a   Owen, G Rh ^b   Meiselman, H J ^c   Beer, J H ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b AO RESEARCH INSTITUTE   (Switzerland)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d KANTONSSPITAL   (Switzerland)

^e NONE

Author keywords

Aggregation; Cyclophosphamide; Erythrocyte; Ifosfamide; Mesna; Viscosity

Indexed keywords

CHLOROACETALDEHYDE; CYCLOPHOSPHAMIDE; IFOSFAMIDE; MESNA;

ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; BRAIN DISEASE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; ECHINOCYTOSIS; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE SHAPE; HUMAN; HUMAN CELL; LIPID BILAYER; PRIORITY JOURNAL; STOMATOCYTOSIS;

EID: 0032963174     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01751.x     Document Type: Article

References (32)

1. 1. Schoenike SE, Dana WJ. Ifosfamide and mesna. Clin Pharmacol 1990;9:179-191.
2. 2. Brade WP, Herdrich K, Kachel-Fischer V, Aranjo CE. Dosing and side-effects of ifosfamide plus mesna. J Cancer Res Clin Oncol 1991;117:(Suppl.IV):S164-S168.
3. 3. Wagner T. Ifosfamide clinical pharmacokinetics. Clin Pharmacokin 1994;26:439-456.
4. 4. Goren M, Wright R, Pratt C. Dechlorethylation of ifosfamide and neurotoxicity. Lancet 1986;2:1219-1220.
5. 5. Küpfer A, Aeschllmann C, Wermuth B, Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet 1994;343:763-764.
6. 6. Brock N, Pohl J, Stekar J. Studies on the uroloxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprolective efficacy of thiols and other sulfur compounds. Eur J Cancer Clin Oncol 1981;17:1155-1163.
7. 7. Shaw I, Graham M. Mesna - a short review. Cancer Treat Rev 1987;14:67-86.
8. 8. Berns JS, Haghighat A, Staddon A, et al. Severe, irreversible renal failure after ifosfamide treatment. Cancer 1995;76:497-500.
9. 9. Baerlocher GM, Beer JH, Owen GRh, Meiselman HJ, Reinhart WH. The antineoplastic drug 5-Fluorouracil produces echinocytosis and affects blood viscosity. Br J Haematol 1997;99:426-32.
10. 10. Bessis M. Red cell shapes. An illustrated classification and its rationales. Nouv Rev Franc Hématol 1972;12:721-746.
11. 11. Reinhart WH, Chien S. Red cell rheology in stomatocyteechinocyte transformation: Roles of cell geometry and cell shape. Blood 1986;67:1110-1118.
12. 12. Ferrell JE Jr, Huestis WH. Phosphoinositide metabolism and the morphology of human erythrocyte. J Cell Biol 1984;98:1992-1998.
13. 13. Richards RG, Gwynn IAP. Backscattered electron imaging of the undersurface of resin-embedded cells by field emission scanning electron microscopy. J Microsc 1995;177:43-52.
14. 14. Schmid-Schönbein H, Volger E, Klose HJ. Microrheology and light transmission of blood. Pflugers Arch 1987;333:140-147.
15. 15. Bauersachs RM, Wenby RB, Meiselman HJ. Determination of specific red blood cell aggregation indices via an automated system. Clin Hemorheol 1989;9:1-25.
16. 16. Koutsouris D, Guillet R, Wenby RB, Meiselman HJ. Determination of erythrocyle transit times through micropores - Influence of experimental and physicochemical factors. Biorheology 1989;25:881-898.
17. 17. Fisher TC, Wenby RB, Meiselman J. Pulse shape analysis of RBC micropore flow via new software for the Cell Transit Analyser (CTA). Biorheology 1992;29:185-201.
18. 18. Sheetz MP, Singer SJ. Equilibrium and kinetic effects of drugs on the shape of human erythrocytes. J Cell Biol 1976;70:247-251.
19. 19. Reinhart WH, Chien S. Echinocyte-stomatocyte-transformation and shape control of human red blood cells: Morphological aspects. Am J Hematol 1987;24:1-14.
20. 20. Alhanaty E, Sheetz MP. Control of the erythrocyte membrane shape: Recovery from the effect of crenating agents. J Cell Biol 1981;91:884-888.
21. 21. Meiselman HJ. Rheology of shape-transformed human red cells. Biorheol 1978;15:225-37.
22. 22. Reinhart WH, Singh-Marchetti M, Straub PW. Influence of erythrocyte shape on suspension viscosities. Eur J Clin Invest 1992;22:38-44.
23. 23. Chien S. Electrochemical interactions and energy balance in red blood cell aggregation In: Milazzo G, ed. Topics in Bioelectrochemistry and Bioenergetics. Chichester: John Wiley, 1981;4:73-112.
24. 24. Fabry TL. Mechanism of erythrocyles aggregation and sedimentation. Blood 1987;70:1572-76.
25. 25. Reinhart WH, Singh A, Straub PW. Red blood cell aggregation and sedimentation: the role of the cell shape. Br J Haematol 1989;73:551-556.
26. 26. Chien S. Biophysical behaviour of red cells in suspension. In: Mac N, Surgenor D, eds. The Red Blood Cell. New York: Academic Press, 1975:1031-133.
27. 2 diffusing capacity and resistance to flow in rabbit lungs. J Appl Physiol 1995;78:778-783.
28. 28. Momerency G, Van Cauwenberghe K, Highley MS, Harper PG, Van Oosterom AT, De Bruijn EA. Partitioning of ifosfamide and its metabolites between red blood cells and plasma. J Pharm Sci 1996;85:262-265.
29. 29. Highley MS, Harper PG, Slee PHThJ, De Bruijn EA. Preferential location of circulating activated cyclophosphamide within the erythrocyte. Int J Cancer 1996;65:711-712.
30. 30. Jacobs H, Amsden T, White J. Membrane microfilaments of erythrocytes: Alteration in intact cells reproduces the hereditary spherocytosis syndrome. Proc Natl Acad Sci USA 1972;69:471-474.
31. 31. Neville AJ, Rand CA, Barr RD, Mohan Pai KR. Drug-induced stomatocytosis and anemia during consolidation chemotherapy of childhood acute leukemia. Am J Med Sci 1984;287:3-7.
32. 32. Levi JA, Aroney RS, Dalley DN. Haemolytic anaemia after cisplatinum treatment. Br Med J 1981;282: 2003-2004.